News from ASCO: Chemotherapy-Free Regimens in NSCLC and CLL

Data from the ASCO 2021 Annual Conference highlighted the durable efficacy of two investigational chemotherapy-free treatments for non-small cell lung cancer (NSCLC) or chronic lymphocytic leukemia (CLL), respectively. An amivantamab-based regimen spurred a clinical benefit response rate of 64% among patients with pre-treated NSCLC, and an all-oral ibrutinib based regimen achieved an overall response rate of 96% in patients with CLL, including more than half who achieved a complete response.